Skip to main content

Ascendis Pharma A/S 6-K, filed Nov 6, 2026

Ascendis Pharma A/S (ASND)

6-K 2026-11-06 For: 2026-11-06
View Original
Added on November 06, 2026

About this 6-K

Ascendis Pharma A/S filed this 6-K on November 6, 2026.

Ascendis Pharma A/S announced a positive EMA opinion recommending continued orphan designation for once-weekly TransCon CNP (navepegritide), potentially providing 10 years of orphan market exclusivity. AI summary